Home
About Us
Overview
Management Team
Board of Directors
Careers
Overview
Life at IMV
The DPX™ Platform
Overview
Scientific Publications & Posters
Clinical Pipeline
Overview
Maveropepimut-S
DPX-RSV
DPX-COVID-19
Clinical Trials
News & Events
Press Releases
Events
Email Alerts
Investors
Overview
Press Releases
Events, Webcasts & Presentations
Financial Info
Stock Data
Filings
Governance
Contact Us
FAQ
Contact
Get in Touch
Safety & Respect
Scientific Publications & Posters
The DPX™ Platform
The DPX™ Platform
Overview
Scientific Publications & Posters
Year:
View All
2022
2021
2020
2019
2018
2016
2015
2014
2013
2012
2011
Indication:
View All
DPX mechanism of action
Infectious Disease
Oncology
SITC, November 2022
DPX-based immune education recruits and activates unique subsets of antigen presenting cells to drive immunogenicity of peptide antigens
SITC, November 2022
Translational analysis of advanced metastatic bladder cancer patients treated with IO combination maveropepimut-S, cyclophosphamide, and pembrolizumab
SITC, November 2022
Neoadjuvant immunotherapy combining maveropepimut-S (MVP-S) with letrozole decreases Ki67 and increases Th1 immune response in hormone receptor positive (HR+) early-stage breast cancer (ESBC)
CRI-ENCI-AACR, September 2022
Cancer-associated fibroblasts as a negative predictor of response to maveropepimut-S, a novel immune educating therapy, in patients with advanced, recurrent ovarian cancer in the DeCidE1 phase 2 trial
RIVKIN - AACR VIRTUAL OVARIAN CANCER RESEARCH SEMINAR SERIES, SEPTEMBER 2022
Maveropepimut-S, a DPX-based immune-educating therapy, shows promising and durable clinical benefit in patients with recurrent ovarian cancer, a single-arm phase II trial
ESMO, SEPTEMBER 2022
VITALIZE: A Phase 2b, Open label, Multicenter, Randomized Parallel Group, Two Stage Study of maveropepimut S, pembrolizumab, with or without Intermittent Low Dose Cyclophosphamide, in r/r DLBCL
ASCO, JUNE 2022
PEmbrolizumab, Maveropepimut-S, and low-dose Cyclophosphamide in advanced epithelial Ovarian cancer: Results from phase 1 and expansion cohort of PESCO trial
ASCO, June 2022
Neoadjuvant survivin-targeted immunotherapy maveropepimut-S (MVP-S) to increase Th1 immune response in Ki67-high hormone receptor positive (HR+) early-stage breast cancer (ESBC)
IMMUNOLOGY 2022, May 2022
Proteomic analysis of plasma exosomes as biomarkers of response to MVP-S based immunotherapy
AACR, APRIL 2022
Safety, preliminary efficacy and pharmacodynamic (PD) analysis of maveropepimut-S, intermittent low-dose cyclophosphamide and pembrolizumab in patients with advanced, metastatic bladder cancer
1
2
3
4
5
Next